MedPath

Mycophenolic acid

Generic Name
Mycophenolic acid
Brand Names
Myfortic
Drug Type
Small Molecule
Chemical Formula
C17H20O6
CAS Number
24280-93-1
Unique Ingredient Identifier
HU9DX48N0T
Background

Mycophenolic acid is a potent immunosuppressant agent that inhibits de novo purine biosynthesis. It was derived from Penicillium stoloniferum, and has also shown antibacterial, antifungal and antiviral properties.. Mycophenolic acid is used in immunosuppressive regimens as part of a triple therapy that includes a calcineurin inhibitor (ciclosporin or tacrolimus) and prednisolone. This regimen can be used in place of the older anti-proliferative azathioprine due to its stronger immunosuppressive potency. However, mycophenolic acid treatment is more expensive and requires therapeutic drug monitoring to optimize efficacy and minimize toxicity. Mycophenolic acid is available as enteric-coated tablets of delayed-release, in an effort to improve upper gastrointestinal adverse events by delaying mycophenolic acid release until it reaches the small intestine. Mycophenolate mofetil, a prodrug of mycophenolic acid, is also prescribed to transplant recipients to prevent organ rejection.

Indication

Mycophenolic acid is an antimetabolite immunosuppressant indicated for prophylaxis of organ rejection in adult patients receiving kidney transplants and in pediatric patients at least 5 years of age and older who are at least 6 months post kidney transplant. Mycophenolic acid is used in combination with cyclosporine and corticosteroids.

Associated Conditions
Kidney Transplant Rejection

Introduction of mTor Inhibitors and the Activation of the Cytomegalovirus (CMV) -Specific Cellular Immune Response

Phase 4
Withdrawn
Conditions
Kidney Transplantation
Cytomegalovirus Infections
Interventions
First Posted Date
2021-06-23
Last Posted Date
2024-02-28
Lead Sponsor
Edoardo Melilli
Registration Number
NCT04936971
Locations
🇪🇸

Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, Spain

Mycophenolate in Limited Cutaneous Systemic Sclerosis (MINIMISE-Pilot)

Phase 2
Active, not recruiting
Conditions
Systemic Sclerosis
Limited Cutaneous Systemic Sclerosis
Interventions
First Posted Date
2021-06-16
Last Posted Date
2023-07-27
Lead Sponsor
University College, London
Target Recruit Count
120
Registration Number
NCT04927390
Locations
🇬🇧

Ninewells Hospital - NHS Tayside, Dundee, United Kingdom

🇬🇧

Royal United Hospitals Bath Nhs Foundation Trust, Bath, United Kingdom

🇬🇧

Southmead Hospital - NORTH BRISTOL NHS TRUST, Bristol, United Kingdom

and more 9 locations

Evaluation of the Effectiveness and Safety of Immunosuppressive and Biological Therapy of Atopic Dermatitis in Childhood

First Posted Date
2021-05-20
Last Posted Date
2021-05-20
Lead Sponsor
National Medical Research Center for Children's Health, Russian Federation
Target Recruit Count
160
Registration Number
NCT04895423
Locations
🇷🇺

National Medical Research Center for Children's Health, Moscow, Russian Federation

A Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Kidney Transplant Recipients Aged 12 to <18 Years to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive Medications

Phase 3
Recruiting
Conditions
Renal Allograft Recipients
Interventions
First Posted Date
2021-05-07
Last Posted Date
2025-04-08
Lead Sponsor
Bristol-Myers Squibb
Target Recruit Count
102
Registration Number
NCT04877288
Locations
🇺🇸

Local Institution - 0022, Hollywood, Florida, United States

🇺🇸

Local Institution - 0045, Miami, Florida, United States

🇺🇸

Local Institution - 0049, Atlanta, Georgia, United States

and more 34 locations

Simplified IMmunosuppressive Protocol Utilizing Low Dose EnvarsusXR

First Posted Date
2021-02-26
Last Posted Date
2023-12-05
Lead Sponsor
University of Southern California
Target Recruit Count
80
Registration Number
NCT04773392
Locations
🇺🇸

University of Southern California, Los Angeles, California, United States

Efficacy and Safety of Sirolimus Plus CNI Compared With MMF Plus CNI in ABO-i Kidney Transplant Recipients.

Phase 4
Not yet recruiting
Conditions
Kidney Transplantation
Interventions
First Posted Date
2021-01-08
Last Posted Date
2021-01-08
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
158
Registration Number
NCT04700709
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

A Study to Evaluate the Safety and Efficacy of Satralizumab in Participants With Neuromyelitis Optica Spectrum Disorder (NMOSD)

Phase 3
Completed
Conditions
Neuromyelitis Optica Spectrum Disorder
Interventions
First Posted Date
2020-12-09
Last Posted Date
2024-12-27
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
119
Registration Number
NCT04660539
Locations
🇺🇸

Jefferson Hospital For Neuroscience; Jefferson Neurology Associates, Philadelphia, Pennsylvania, United States

🇺🇸

University of Texas Southwestern Medical Center, Dallas, Texas, United States

🇺🇸

University of Chicago, Chicago, Illinois, United States

and more 50 locations

Evaluating the Safety of Myfortic (Mycophenolate Sodium) in Patients With Lupus Nephritis

Active, not recruiting
Conditions
Lupus Nephritis
Interventions
First Posted Date
2020-11-27
Last Posted Date
2025-03-25
Lead Sponsor
Novartis Pharmaceuticals
Target Recruit Count
64
Registration Number
NCT04645589
Locations
🇨🇳

Novartis Investigative Site, Taoyuan, Taiwan

Randomized Trial Evaluating Mycophenolate Mofetil in Children With Nephrotic Syndrome After Rituximab Treatment

Phase 3
Withdrawn
Conditions
Frequently Relapsing Nephrotic Syndrome
Steroid-Dependent Nephrotic Syndrome
Interventions
First Posted Date
2020-08-31
Last Posted Date
2020-12-29
Lead Sponsor
Children's Hospital of Fudan University
Registration Number
NCT04531865
Locations
🇨🇳

Xinhua Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China

🇨🇳

Children's hospital of Fudan university, Shanghai, Shanghai, China

🇨🇳

Shanghai Children's Hospital, Shanghai, China

and more 1 locations

Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.

Phase 4
Conditions
Liver Transplant
Interventions
First Posted Date
2020-07-15
Last Posted Date
2020-07-15
Lead Sponsor
Chong Kun Dang Pharmaceutical
Target Recruit Count
150
Registration Number
NCT04471441
Locations
🇰🇷

Severance Hospital, Seoul, Korea, Republic of

© Copyright 2025. All Rights Reserved by MedPath